Q-omics provides the consensus-scored MIR590 profile across patient tissues and cancer cell-line models. MIR590 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR590 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, MIR590 RNA expression shows 18,590 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BRCA, and THYM as cancer lineages where MIR590 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR590 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR590 survival associations across molecular data types. MIR590 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR590 RNA expression–survival associations across cancer types. High MIR590 expression shows unfavorable associations in UVM, LGG, CESC and LUSC, but favorable associations in HNSC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR590 RNA expression.
This table summarizes MIR590 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR590. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR590 shows lower tumor expression in BRCA, LUSC and THCA and higher tumor expression in KIRC, BLCA and CHOL. The BRCA box plot shows higher MIR590 RNA expression in normal versus tumor tissue (log2 FC = −1.168, t-test p < 0.001).
This table shows molecular features associated with MIR590 in patient tissues and cancer cell lines. In patient samples, MIR590 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
